JP2012176990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012176990A5 JP2012176990A5 JP2012137900A JP2012137900A JP2012176990A5 JP 2012176990 A5 JP2012176990 A5 JP 2012176990A5 JP 2012137900 A JP2012137900 A JP 2012137900A JP 2012137900 A JP2012137900 A JP 2012137900A JP 2012176990 A5 JP2012176990 A5 JP 2012176990A5
- Authority
- JP
- Japan
- Prior art keywords
- calcium salt
- formulation
- used according
- active ingredient
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 159000000007 calcium salts Chemical class 0.000 claims 17
- 238000009472 formulation Methods 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 16
- 239000004480 active ingredient Substances 0.000 claims 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 229940124630 bronchodilator Drugs 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical group [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003843 mucus production Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68235605P | 2005-05-18 | 2005-05-18 | |
| US60/682,356 | 2005-05-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512543A Division JP2008540680A (ja) | 2005-05-18 | 2006-05-18 | 粘膜内壁の生物物理学的な性質を変化させる製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012176990A JP2012176990A (ja) | 2012-09-13 |
| JP2012176990A5 true JP2012176990A5 (https=) | 2012-10-25 |
Family
ID=37401509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512543A Pending JP2008540680A (ja) | 2005-05-18 | 2006-05-18 | 粘膜内壁の生物物理学的な性質を変化させる製剤 |
| JP2012137900A Pending JP2012176990A (ja) | 2005-05-18 | 2012-06-19 | 粘膜内壁の生物物理学的な性質を変化させる製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512543A Pending JP2008540680A (ja) | 2005-05-18 | 2006-05-18 | 粘膜内壁の生物物理学的な性質を変化させる製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20070053844A1 (https=) |
| EP (3) | EP2402001A1 (https=) |
| JP (2) | JP2008540680A (https=) |
| KR (1) | KR20080018872A (https=) |
| CN (2) | CN101237853A (https=) |
| AU (1) | AU2006247077A1 (https=) |
| BR (1) | BRPI0609924A2 (https=) |
| CA (1) | CA2608752A1 (https=) |
| EA (1) | EA016072B1 (https=) |
| IL (1) | IL187427A0 (https=) |
| NO (1) | NO20076086L (https=) |
| NZ (2) | NZ593475A (https=) |
| WO (1) | WO2006125153A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050207983A1 (en) * | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
| CA2754691C (en) * | 2009-03-26 | 2019-07-30 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| US20120058198A1 (en) * | 2009-03-26 | 2012-03-08 | Pulmatrix, Inc. | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis |
| JP2012522011A (ja) * | 2009-03-26 | 2012-09-20 | パルマトリックス，インコーポレイテッド | 気道感染症を治療するための医薬製剤および方法 |
| CA2754684A1 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining |
| CA2754670A1 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Anti-influenza formulations and methods |
| EP2464346A1 (en) | 2010-08-30 | 2012-06-20 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| RU2017144619A (ru) | 2010-09-29 | 2019-02-20 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
| EP3470057B1 (en) | 2010-09-29 | 2021-11-03 | Pulmatrix Operating Company, Inc. | Cationic dry powders comprising magnesium salt |
| WO2013052844A1 (en) | 2011-10-07 | 2013-04-11 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
| CN107596518B (zh) | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
| JP6473738B2 (ja) | 2013-04-01 | 2019-02-20 | パルマトリックス，インコーポレイテッド | チオトロピウム乾燥粉末 |
| US9987235B2 (en) * | 2013-08-01 | 2018-06-05 | Nicholas L. Abbott | Methods and compositions for modifying mucous membranes |
| WO2016067252A1 (en) | 2014-10-31 | 2016-05-06 | Glaxosmithkline Intellectual Property Development Limited | Powder formulation |
| ES2862700T3 (es) * | 2015-11-18 | 2021-10-07 | The Board Of Trustees Of The Leland Stanford Junior Univ Office Of The General Counsel | Péptido para utilizar en el tratamiento de afecciones médicas con componentes inflamatorios o autoinmunes |
| WO2019139479A1 (en) * | 2018-01-11 | 2019-07-18 | Rob Janssen | Compositions and methods for the treatment of lung emphysema and other forms of copd |
| EP3846825A4 (en) | 2018-09-05 | 2022-11-02 | Sensory Cloud, LLC | FORMULATIONS AND COMPOSITIONS FOR ORTHO- AND/OR RETRO-NASAL DELIVERY AND RELATED SYSTEMS, METHODS AND ARTICLES |
| US12128067B2 (en) | 2018-11-29 | 2024-10-29 | Yildiz Teknik Universitesi | Nasal solution with closed basin natural spring water characteristic and method for obtaining said nasal solution |
| US20230218661A1 (en) * | 2022-01-10 | 2023-07-13 | Sensory Cloud, Inc. | Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx |
| US20220000767A1 (en) * | 2020-07-06 | 2022-01-06 | Sensory Cloud, Inc. | Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi |
| WO2022040247A1 (en) * | 2020-08-17 | 2022-02-24 | Massachusetts Institute Of Technology | Respiratory system simulator systems and methods |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3229179C2 (de) * | 1982-08-05 | 1986-04-17 | A. Nattermann & Cie GmbH, 5000 Köln | Lungensurfactant |
| US4637815A (en) * | 1985-08-06 | 1987-01-20 | Lemole Gerald M | Irrigational hemostatic solution |
| US5230884A (en) * | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
| US5175152A (en) * | 1990-09-28 | 1992-12-29 | Singh Nikhilesh N | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
| US5571535A (en) * | 1990-11-30 | 1996-11-05 | Flowers; Marianne | Treatment of topical infections |
| US5466680A (en) * | 1992-03-26 | 1995-11-14 | Cytologics, Inc. | Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
| US5898037A (en) * | 1992-11-13 | 1999-04-27 | Marx; Alvin J. | Formulations of magnesium compounds for local application and methods of treatment using the same |
| US5709202A (en) | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
| AUPM411494A0 (en) * | 1994-02-25 | 1994-03-24 | Central Sydney Area Health Service | Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum |
| US5633003A (en) * | 1994-03-31 | 1997-05-27 | Cantor; Jerome O. | Use of intratracheally administered hyaluronic acid to ameliorate emphysema |
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| JP3061862B2 (ja) * | 1994-10-14 | 2000-07-10 | 山之内製薬株式会社 | アゾール誘導体 |
| WO1996013254A1 (en) * | 1994-10-26 | 1996-05-09 | Glaxo Wellcome House | Pharmaceutical composition comprising atovaquone |
| US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US5628984A (en) * | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| US6083922A (en) * | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US6254854B1 (en) * | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| USRE37053E1 (en) * | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
| AU749751B2 (en) * | 1998-04-08 | 2002-07-04 | Eli Lilly And Company | Pulmonary and nasal delivery of raloxifene |
| US5883084A (en) * | 1998-06-08 | 1999-03-16 | Clarion Pharmaceuticals Inc. | Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine |
| FR2780285B1 (fr) * | 1998-06-29 | 2001-10-05 | Goemar Lab Sa | Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions |
| US6333051B1 (en) * | 1998-09-03 | 2001-12-25 | Supratek Pharma, Inc. | Nanogel networks and biological agent compositions thereof |
| AU4979700A (en) * | 1999-05-03 | 2000-11-17 | Battelle Memorial Institute | Compositions for aerosolization and inhalation |
| US6858199B1 (en) * | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| AU772096B2 (en) * | 2000-03-14 | 2004-04-08 | Sumika Enviro-Science Co., Ltd. | Method for denaturing allergens |
| JP3481205B2 (ja) * | 2000-11-24 | 2003-12-22 | 松下電器産業株式会社 | インバータ制御用半導体装置および制御方法 |
| CA2432319A1 (en) * | 2000-12-21 | 2002-07-18 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| WO2003072080A1 (en) * | 2002-02-22 | 2003-09-04 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
| AU2003243191B2 (en) | 2002-05-02 | 2007-09-20 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections |
| EP1503744A1 (en) * | 2002-05-13 | 2005-02-09 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
| JP4533134B2 (ja) * | 2002-06-10 | 2010-09-01 | エラン ファーマ インターナショナル，リミティド | ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ |
| US7534781B2 (en) * | 2003-03-21 | 2009-05-19 | Dsm Ip Assets B.V. | Crystalline amoxicillin trihydrate powder |
| JP2009514779A (ja) * | 2003-07-11 | 2009-04-09 | グラクソ グループ リミテッド | 医薬製剤 |
| GB0324897D0 (en) * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
| US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
| SE528121C2 (sv) * | 2004-03-29 | 2006-09-05 | Mederio Ag | Preparering av torrpulver för på förhand uppmätt DPI |
| CA2602596A1 (en) * | 2004-03-30 | 2005-10-13 | Malcolm King | Compositions and methods for improved mucus function |
| MX2007000979A (es) * | 2004-07-26 | 2007-07-11 | Cotherix Inc | Tratamiento de la hipertension pulmonar por iloprost inhalado con una formulacion microparticulada. |
| US20070202051A1 (en) * | 2006-02-10 | 2007-08-30 | Pari Gmbh | Aerosols for sinunasal drug delivery |
| GB0818476D0 (en) * | 2008-10-09 | 2008-11-12 | Vectura Delivery Device Ltd | Inhaler |
| CA2754670A1 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Anti-influenza formulations and methods |
-
2006
- 2006-05-18 EP EP11177874A patent/EP2402001A1/en not_active Withdrawn
- 2006-05-18 KR KR1020077027567A patent/KR20080018872A/ko not_active Ceased
- 2006-05-18 NZ NZ593475A patent/NZ593475A/xx unknown
- 2006-05-18 JP JP2008512543A patent/JP2008540680A/ja active Pending
- 2006-05-18 US US11/419,165 patent/US20070053844A1/en not_active Abandoned
- 2006-05-18 CN CNA2006800261749A patent/CN101237853A/zh active Pending
- 2006-05-18 BR BRPI0609924-6A patent/BRPI0609924A2/pt not_active IP Right Cessation
- 2006-05-18 EA EA200702520A patent/EA016072B1/ru not_active IP Right Cessation
- 2006-05-18 WO PCT/US2006/019443 patent/WO2006125153A2/en not_active Ceased
- 2006-05-18 AU AU2006247077A patent/AU2006247077A1/en not_active Abandoned
- 2006-05-18 CA CA002608752A patent/CA2608752A1/en not_active Abandoned
- 2006-05-18 EP EP10014830A patent/EP2308469A1/en not_active Withdrawn
- 2006-05-18 CN CN2011102255478A patent/CN102327285A/zh active Pending
- 2006-05-18 NZ NZ564110A patent/NZ564110A/en unknown
- 2006-05-18 EP EP06770654A patent/EP1906922A2/en not_active Withdrawn
-
2007
- 2007-11-15 IL IL187427A patent/IL187427A0/en unknown
- 2007-11-27 NO NO20076086A patent/NO20076086L/no not_active Application Discontinuation
-
2012
- 2012-06-19 JP JP2012137900A patent/JP2012176990A/ja active Pending
-
2014
- 2014-11-14 US US14/541,648 patent/US20150196589A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012176990A5 (https=) | ||
| EP1954258B1 (en) | Materials and methods for treating influenza viral infections with a cysteamine compound | |
| Pham et al. | Strategies for the design of orally bioavailable antileishmanial treatments | |
| JP2013126989A5 (https=) | ||
| JP2015509788A5 (https=) | ||
| RU2017144619A (ru) | Катионы одновалентных металлов сухих порошков для ингаляций | |
| MX2009011218A (es) | Microparticulas de acido nucleico para administracion pulmonar. | |
| EP3988102B1 (en) | Medicament for prevention or treatment of rhinovirus infection | |
| WO2005084638A3 (en) | Formulations decreasing infectivity of pulmonary diseases | |
| NZ602441A (en) | A fast dissolving pharmaceutical composition | |
| PT2249866E (pt) | Uso de um sal de ácido acetilsalicílico para o tratamento de infecções virais | |
| WO2016044839A2 (en) | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds | |
| US20250049862A1 (en) | Spray dried inhalable biotherapeutics for the treatment of disease | |
| JP2016535094A5 (https=) | ||
| Rios-Ibarra et al. | Nanoparticle‑based antiviral strategies to combat the influenza virus | |
| CA2991156A1 (en) | Compositions and methods for the treatment of viral infection | |
| JP2013515490A5 (https=) | ||
| WO2015049519A3 (en) | Method and apparatus for making compositions for pulmonary administration | |
| CN101842092A (zh) | 用于治疗流感感染的材料和方法 | |
| CN101340902B (zh) | 用半胱胺化合物处理病毒感染的材料和方法 | |
| JP2024529291A (ja) | ウイルス感染症の処置および予防のための組成物および方法 | |
| WO2022150709A1 (en) | Compositions and methods for treating viral infection | |
| US20240075012A1 (en) | Compositions and methods for treating viral infection | |
| EA201201362A1 (ru) | Фармацевтический аэрозольный состав ингибиторов протеаз и его получение | |
| CN111971034A (zh) | 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用 |